Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Eravacycline (Xerava) is indicated for the treatment of complicated intra-abdominal infections in patients 18 years of age and older.
• The information was derived from a total of five systematic reviews/meta-analyses.
• In comparison to carbapenems, eravacycline shows no significant difference in clinical cure rates across various populations, including clinically evaluable, microbiologically evaluable, and modified intention-to-treat groups.
• Safety profiles indicate that eravacycline has similar rates of adverse events compared to carbapenems but may have higher odds for minor adverse events like nausea; however, it does not significantly differ in serious adverse events or discontinuation due to side effects.
• Subgroup analysis highlights that most studies involved lower-risk patients with APACHE II scores <10. Specific data on concurrent bacteremia showed promising results for eravacycline's effectiveness and safety comparable to carbapenem treatments.
• Overall findings suggest that while cefepime plus metronidazole might be more efficacious as an empirical treatment option, eravacycline remains a viable alternative, particularly as a carbapenem-sparing agent.